Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07232108

Intrathecal Morphine Versus Trocar-Site and Intraperitoneal Bupivacaine for Quality of Recovery After Laparoscopic Hysterectomy

This study aims to compare the effects of intrathecal morphine with trocar-site infiltration and intraperitoneal bupivacaine on postoperative pain control, quality of recovery, and inflammatory response in patients undergoing elective laparoscopic hysterectomy. Laparoscopic hysterectomy is widely used for benign gynecologic conditions, but postoperative pain may result from trocar-site trauma, peritoneal irritation, and carbon dioxide insufflation. Effective postoperative analgesia can improve patient comfort, reduce opioid use, and enhance early recovery.

Intrathecal morphine is known to provide potent early postoperative analgesia but may cause side effects such as nausea, vomiting, pruritus, and respiratory depression. Local anesthetic techniques, including trocar-site infiltration and intraperitoneal bupivacaine, have also been shown to reduce postoperative pain after minimally invasive gynecologic surgery.

In this prospective, randomized, double-blind study, patients will be assigned to one of two groups:

Intrathecal morphine (ITM) administered before induction of anesthesia;

Local anesthesia group (LA) receiving trocar-site infiltration and intraperitoneal bupivacaine at the end of surgery.

The primary outcome is the Quality of Recovery-15 (QoR-15) score at 24 hours. Secondary outcomes include pain scores, opioid consumption, time to first rescue analgesia, postoperative nausea and vomiting, pruritus, respiratory depression, early mobilization, bowel function recovery, and perioperative inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII).

The results of this trial are expected to guide clinicians in selecting optimal analgesic strategies for laparoscopic hysterectomy and to contribute to improved patient recovery and postoperative satisfaction.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ataturk University

Erzurum, 25000, Turkey (Türkiye)

Location status: Recruiting

Location contact

Mehmet Akif Yılmaz, assistant doctor

CONTACT

[email protected]

+90-534-653-35-39

About this study

Study Background and Rationale:

Despite its minimally invasive advantages, laparoscopic hysterectomy can cause significant postoperative pain due to trocar sites, visceral manipulation, and peritoneal irritation. This pain results in opioid consumption, associated side effects, and delayed recovery. Multimodal analgesia is the cornerstone of postoperative care. In this context, trocar site infiltration with intrathecal morphine (long-acting central analgesia) and intraperitoneal local anesthetic administration (peripheral techniques targeting somatic and visceral pain) are effective options. This study aims to compare the effects of these two different analgesic strategies on the quality of postoperative recovery through a patient-centered outcome measure, the QoR-15, and objective hematologic inflammatory markers.

Technical Details of Intervention Protocols:

General Anesthesia Standardization: All patients will receive standard general anesthesia. Induction will be achieved with propofol and fentanyl, rocuronium bromide will be used for neuromuscular blockade, and anesthesia will be maintained with sevoflurane.

Group ITM (Intrathecal Morphine) Intervention: Before induction of general anesthesia, patients will be in the sitting or lateral decubitus position and 200 µg (0.2 mg) of morphine will be injected into the subarachnoid space with a 25G (or 27G) pencil-point spinal needle at the L3-L4 intervertebral space. Hemodynamic and respiratory parameters will be closely monitored for 30 minutes after the injection.

Group LA (Local Anesthetic) Intervention: At the end of the surgical procedure, 5 mL of 0.25% bupivacaine will be infiltrated into each trocar incision. Additionally, 40 mL of 0.25% bupivacaine will be administered intraperitoneally, distributing to the subhepatic, diaphragmatic, and pelvic surfaces. The total bupivacaine dose will be calculated to avoid exceeding 2 mg/kg body weight to avoid the risk of toxicity.

Standard Perioperative Medication Regimen: All patients in both groups will receive the following medications intraoperatively as part of multimodal analgesia: 1 g Paracetamol, 800 mg Ibuprofen, 3 mg Granisetron, 40 mg Esomeprazole, and 8 mg Dexamethasone.

Methodological Details for Outcome Assessments:

QoR-15 Questionnaire: The validated and reliable Turkish version of the primary outcome measure, QoR-15, will be used. The questionnaire will be administered before surgery to obtain preoperative baseline values and at 24 hours postoperatively as the primary outcome.

Pain and Side Effect Monitoring: Postoperative pain will be assessed using a Visual Analog Scale (VAS: 0-10 cm) at rest and during coughing/activity. Assessments will be made at 2-hour intervals from the 2nd postoperative hour to the 24th hour. Nausea, vomiting, pruritus, and respiratory depression (SpO2 < 90% or respiratory rate < 8/minute) will be recorded using standard forms.

Hematological Inflammatory Markers: A complete blood count will be analyzed using an automated hematology analyzer from venous blood samples taken preoperatively (baseline, T0) and at the 24th postoperative hour (T13). Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR), Lymphocyte/Monocyte Ratio (LMR), and Systemic Immuno-Inflammation Index (SII = (Platelet count x Neutrophil count) / Lymphocyte count) will be calculated.

Blinding Protocol: Except for the anesthesiologist who performs the randomization and intervention, the patients, the surgical team, the investigators collecting postoperative data, and the statistical analyst will be blinded to group distinctions. Randomization will be stored using sequential, numbered, opaque envelopes.

Clinical Significance of the Study:

The findings of this study may provide evidence-based recommendations regarding the most effective multimodal analgesia regimen after laparoscopic hysterectomy. The demonstrated superiority of intrathecal morphine in reducing the systemic inflammatory response and patient-reported quality of recovery may result in less opioid use and faster recovery. Conversely, if local anesthetic techniques are adequate, the potential risks of central block may be avoided.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients aged 18-65 years.
  • Elective laparoscopic hysterectomy planned for benign gynecological conditions.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Ability to provide written informed consent.

Exclusion criteria

  • Coagulopathy or bleeding disorders.
  • Opioid dependence or chronic opioid use.
  • Allergy or contraindication to local anesthetics or morphine.
  • Contraindication to neuraxial (spinal) anesthesia.
  • History of chronic pain syndromes.
  • Severe renal or hepatic dysfunction.
  • Pregnancy or breastfeeding.

Treatment and study plan

Intrathecal morphine

Drug

A single dose of 200 µg preservative-free morphine will be administered intrathecally at the L3-L4 interspace prior to induction of general anesthesia. The injection is performed using a 25G spinal needle. This intervention aims to provide prolonged early postoperative analgesia in patients undergoing laparoscopic hysterectomy.

Trocar-Site Bupivacaine Infiltration

Drug

At the end of laparoscopic hysterectomy, 5 mL of 0.25% bupivacaine will be infiltrated into each trocar site. This intervention targets somatic pain originating from trocar entry points. It is administered only in the Local Anesthesia (LA) Group. The total dose of bupivacaine from all applications will remain within recommended safety limits.

Intraperitoneal Bupivacaine spray

Drug

A total of 40 mL of 0.25% bupivacaine will be instilled intraperitoneally after completion of the surgical procedure. This intervention is designed to reduce visceral and peritoneal irritation-related pain following laparoscopic hysterectomy. The combined bupivacaine dose from trocar-site infiltration and intraperitoneal instillation will not exceed 2 mg/kg.

Primary outcomes

  1. Postoperative quality of recovery at 24 hours measured by QoR-15

    Time frame: 24 hours postoperatively

    The primary outcome is the overall postoperative recovery quality at 24 hours, assessed using the 15-item Quality of Recovery questionnaire (QoR-15). This scale evaluates physical comfort, emotional state, physical independence, psychological support, and pain to provide a comprehensive patient-centered measure of recovery.

Secondary outcomes

  1. Time to first rescue opioid requirement

    Time frame: From end of surgery until first rescue opioid administration (up to 24 hours)

    Duration (in hours) from the end of surgery to the first administration of rescue opioid (oxycodone 5 mg) for postoperative pain relief.

  2. Total opioid consumption within 24 hours

    Time frame: 0-24 hours postoperatively

    Total amount of rescue opioid consumed by the patient within the first 24 hours after surgery, expressed in milligrams.

  3. Time to first mobilization

    Time frame: 0-24 hours postoperatively

    Time (in hours) from the end of surgery until the patient is able to ambulate independently for the first time postoperatively.

  4. Time to first bowel movement

    Time frame: 0-24 hours postoperatively

    Time (in hours) from the end of surgery until the patient reports the first postoperative bowel movement.

  5. Postoperative pain scores (VAS)

    Time frame: 2-24 hours postoperatively

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a continuous scale ranging from 0 to 10. Scores are recorded by patients marking a line, where 0 represents "no pain" and 10 represents "the worst pain imaginable". Higher scores indicate a worse outcome (more severe pain). Assessments will be performed at rest and during movement (e.g., coughing) at 2-hour intervals from 2 to 24 hours postoperatively.

  6. Postoperative complications

    Time frame: 0-24 hours postoperatively

    Incidence of postoperative nausea, vomiting, pruritus, and respiratory depression within the first 24 hours after surgery.

  7. Neutrophil-to-lymphocyte ratio (NLR)

    Time frame: Preoperative baseline and 24 hours postoperatively

    NLR measured preoperatively and at 24 hours postoperatively to evaluate systemic inflammatory response.

  8. Platelet-to-lymphocyte ratio (PLR)

    Time frame: Preoperative baseline and 24 hours postoperatively

    PLR measured preoperatively and at 24 hours postoperatively to evaluate systemic inflammatory response.

  9. Lymphocyte-to-monocyte ratio (LMR)

    Time frame: Preoperative baseline and 24 hours postoperatively

    LMR measured preoperatively and at 24 hours postoperatively to evaluate systemic inflammatory response.

  10. Systemic immune-inflammation index (SII)

    Time frame: Preoperative baseline and 24 hours postoperatively

    SII measured preoperatively (T0) and at 24 hours postoperatively (T13) to evaluate systemic inflammatory response.

Study contacts

Contact information is provided by the study sponsor or research team.

Ayşenur Dostbil, Associate Professor

CONTACT

[email protected]

+90-533-367-66-96

Mehmet Akif Yılmaz, assistant doctor

CONTACT

[email protected]

+90-534-653-35-39

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

Effects of Intrathecal Morphine Compared With Trocar-Site Infiltration and Intraperitoneal Bupivacaine on Postoperative Quality of Recovery and Inflammatory Markers After Laparoscopic Hysterectomy: A Prospective, Randomized, Double-Blind Controlled Trial

Acronym: ITM-LH-QoR

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 18, 2025
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.